StocktwitsEarnings
Nov 4, 1:09 PM
$NVCT Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of -
$0.20 up 54.55% YoY
• Nuvectis Pharma expects research and development expenses to increase substantially in the near term and beyond, and general and administrative expenses to increase in the future as headcount expands to support development and corporate activities.
0 replies